238 related articles for article (PubMed ID: 24076645)
1. [Updates on rickets and osteomalacia: anti-FGF23 antibody, a new therapeutic approach for hypophosphatemic rickets/osteomalacia].
Shimada T
Clin Calcium; 2013 Oct; 23(10):1469-75. PubMed ID: 24076645
[TBL] [Abstract][Full Text] [Related]
2. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
3. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
4. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
5. [Rickets/Osteomalacia. FGF23-related hypophosphatemic rickets/osteomalacia.].
Fukumoto S
Clin Calcium; 2018; 28(10):1313-1317. PubMed ID: 30269112
[TBL] [Abstract][Full Text] [Related]
6. Advances in understanding of phosphate homeostasis and related disorders.
Michigami T
Endocr J; 2022 Aug; 69(8):881-896. PubMed ID: 35831119
[TBL] [Abstract][Full Text] [Related]
7. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
Fukumoto S
Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
[TBL] [Abstract][Full Text] [Related]
8. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
[TBL] [Abstract][Full Text] [Related]
9. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
10. Anti-fibroblast growth factor 23 antibody therapy.
Fukumoto S
Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
12. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia].
Kinoshita Y; Fukumoto S
Clin Calcium; 2014 Aug; 24(8):1217-22. PubMed ID: 25065874
[TBL] [Abstract][Full Text] [Related]
13. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice.
Ohata Y; Yamazaki M; Kawai M; Tsugawa N; Tachikawa K; Koinuma T; Miyagawa K; Kimoto A; Nakayama M; Namba N; Yamamoto H; Okano T; Ozono K; Michigami T
J Bone Miner Res; 2014 Jul; 29(7):1627-38. PubMed ID: 24470103
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
15. FGF23 Neutralizing Antibody Partially Improves Bone Mineralization Defect of HMWFGF2 Isoforms in Transgenic Female Mice.
Xiao L; Homer-Bouthiette C; Hurley MM
J Bone Miner Res; 2018 Jul; 33(7):1347-1361. PubMed ID: 29502359
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
Goldsweig BK; Carpenter TO
Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
[TBL] [Abstract][Full Text] [Related]
17. Hypophosphatemic rickets.
Baroncelli GI; Toschi B; Bertelloni S
Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):460-7. PubMed ID: 23108197
[TBL] [Abstract][Full Text] [Related]
18. [FGF23-related hypophosphatemic rickets/osteomalacia].
Ito N; Fukumoto S
Clin Calcium; 2007 Oct; 17(10):1514-20. PubMed ID: 17906402
[TBL] [Abstract][Full Text] [Related]
19. [Clinical aspect of recent progress in phosphate metabolism. The pathophysiology of diseases caused by aberrant actions of FGF23].
Shimizu Y; Fukumoto S
Clin Calcium; 2009 Jun; 19(6):802-7. PubMed ID: 19483274
[TBL] [Abstract][Full Text] [Related]
20. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
